Ignite Creation Date:
2025-12-24 @ 7:09 PM
Ignite Modification Date:
2025-12-28 @ 3:55 PM
Study NCT ID:
NCT05952557
Status:
RECRUITING
Last Update Posted:
2025-06-19
First Post:
2023-05-17
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)
Sponsor:
AstraZeneca
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2023-10-05
Start Date Type:
ACTUAL
Primary Completion Date:
2030-03-04
Primary Completion Date Type:
ESTIMATED
Completion Date:
2037-05-06
Completion Date Type:
ESTIMATED
First Submit Date:
2023-05-17
First Submit QC Date:
None
Study First Post Date:
2023-07-19
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-06-18
Last Update Post Date:
2025-06-19
Last Update Post Date Type:
ACTUAL